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One Sentence Summary: Human umbilical cord perivascular mesenchymal stromal cells 
improve vascularization and glycemic control of human islets implanted in mice. 
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Abstract: Islet transplantation is an efficacious therapy for Type 1 diabetes, however islets 
from multiple donor pancreata are required and a gradual attrition in transplant function is seen. 
Here we manufactured human umbilical cord perivascular mesenchymal stromal cells 
(HUCPVCs) to Good Manufacturing Practice (GMP) standards. HUCPVCs showed a stable 
phenotype while undergoing rapid ex vivo expansion at passage 2-4 and produced pro-
regenerative factors, strongly suppressing T cell responses in the resting state and in response 
to inflammation. Transplanting an islet equivalent (IEQ):HUCPVC ratio of 1:30 under the 
kidney capsule in diabetic humanized NSG mice demonstrated the fastest return to 
normoglycemia by 3 days post-transplant: Superior glycemic control was seen at both early 
(2.7 weeks) and later stages (7, 12, and 16 weeks) versus ratios of 1:0, 1:10, and 1:50, 
respectively. Syngeneic islet transplantation in immunocompetent mice using the clinically-
relevant hepatic portal route with a marginal islet mass showed that mice transplanted with an 
IEQ:HUCPVC ratio of 1:150 had superior glycemic control versus ratios of 1:0, 1:90, and 
1:210 up to 6 weeks post-transplant. Immunodeficient mice transplanted with human islets 
(IEQ:HUCPVC ratio of 1:150) exhibited better glycemic control for 7 weeks post-transplant 
versus islet transplant alone, and islets transplanted via the hepatic portal vein in an allogeneic 
mouse model using a curative islet mass demonstrated delayed rejection of islets when co-
transplanted with HUCPVCs (IEQ:HUCPVC ratio of 1:150). The immunosuppressive and pro-
regenerative properties of HUCPVCs demonstrated long-term positive effects on graft function 
in vivo, indicating they may improve long-term human islet allotransplantation outcomes. 
 
INTRODUCTION 
Islet transplantation is effective for stabilizing glycemic control and restoring awareness of 
hypoglycemia in people with Type 1 diabetes (1-9), and there is evidence of diminished 
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progression of microvascular and macrovascular complications (10). However, transplant is 
suboptimal and individuals typically require two to three islet transplants to improve their 
glycemic control (4). Inflammatory and immunological rejection mechanisms lead to the early 
loss of islets (11, 12) and contribute to the attrition in graft function seen over time (4). Repeat 
immune sensitization events may arise due to the necessity for multiple transplants. 
Furthermore, the number of people that may receive transplants is limited by the availability 
of suitable donor pancreata (13).Therapeutic strategies to improve graft function are urgently 
needed. Ideally, a therapeutic strategy would modulate the inflammatory and immune response 
and enhance engraftment of islets through a variety of mechanisms, reducing the need for 
multiple transplants and high doses of immunosuppression. This would allow more patients to 
be treated and would enable the use of pancreata with marginal numbers of isolated islets to be 
used.  
Mesenchymal stromal cells (MSCs) are multipotent cells found in most tissues which 
are capable of self-renewal and have potential for tri-lineage differentiation: osteogenic, 
adipogenic, and chondrogenic (14). They have been shown to promote regeneration of tissues 
by supporting blood vessel formation through production of a broad spectrum of growth factors 
and extracellular matrix building molecules (15). MSCs suppress the host immune response, 
both innate and adaptive pathways, through activating anti-inflammatory factors, suppressing 
B- and T-cell proliferation, and increasing production of regulatory T-cells and polarized M2 
macrophages. Such functions are highly relevant to the therapy of the chronic inflammatory 
autoimmune disease Type 1 diabetes (16). 
Bone marrow-derived MSCs (bmMSCs) have been the gold standard in clinical 
practice, enhancing donor bone marrow cell engraftment and chimerism (17), and have been 
co-transplanted with islets in animal models of diabetes with favorable effects on graft function 
and longevity (18). However, bmMSCs are present at low frequency in the marrow 
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compartment, cell harvesting is painful and invasive, and bmMSCs also exhibit a reduced ex 
vivo expansion capacity as donor age increases (19). MSCs from other sites, including 
umbilical cord, have been used in animal models of diabetes, although not in animal models of 
islet transplantation (20). Cellular preparations derived from umbilical cord can be obtained in 
clinically-relevant quantities with procurement advantages: cell harvesting is non-invasive, and 
cells are highly expandable ex vivo. Preparations from umbilical cord, which include MSC-
type cells and other cell types (epithelial),  can undergo freeze thaw cycles for off-the-shelf use 
(21) and have been used in clinical trials  (20, 21). However, before such MSCs can be used in 
clinical islet allotransplantation they must be fully characterized, demonstrate greater efficacy 
on co-transplantation with islets versus islet transplantation alone, and they must be compliant 
with GMP.  
There have been no studies in islet transplantation in man using allogeneic MSCs. MSC 
studies in Type 1 diabetes are heterogeneous and difficult to compare because the numbers and 
types of MSCs used have differed, the time interval between diagnosis of diabetes and infusion 
of stem cells is highly variable, and some studies use autologous whereas other studies use 
allogeneic stem cells (22; 23). No studies in man have developed and/or characterized GMP 
compliant umbilical cord MSCs for co-transplant with islets or have systematically examined 
the islet:MSC ratio, which has the greatest impact on short, and long, term glycemic control.  
Here, we have adapted existing methods for production of well characterized human 
HUCPVC (24-27) to a fully GMP compliant, xeno-free culture system. Our aims were to 
repeatedly derive and characterize GMP grade HUCPVCs with respect to immune regulatory 
and regenerative properties in vitro, their metabolic efficacy in co-transplantation experiments 
with islets in vivo [including infusion via the hepatic portal vein (HPV) route used in human 
transplantation], and to quantify islet graft vascularization using rodent models of islet 
transplantation.   
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RESULTS  
Generation of GMP grade HUCPVCs with stable MSC phenotype  
Six donations of umbilical cord were processed into HUCPVC lines, frozen after the initial 
seed culture was established, and then thawed and expanded up to passage 4 (p4) using 3 GMP 
compliant media: StemMACS (SM), SM + group AB donor plasma (SMAB), and SM + 
platelet lysate (SMPL). HUCPVCs exhibited the characteristic MSC phenotype [International 
Society for Cellular Therapy criteria (28)]: expressing the markers CD73, CD90, and CD105 
but negative for expression of CD34, CD45, CD14, and CD11b (Fig. 1A). HUCPVCs also 
consistently expressed CD10, which is definitively associated with perivascular cells of the 
Wharton’s Jelly (29, 30). SMPL gave the shortest population doubling times, however, 
differences were not significant and all 3 media gave satisfactory results (Fig. 1B). The 
HUCPVC phenotype was stable throughout serial passage of the cells and HUCPVCs 
maintained similar stemness potential in all media, assessed by Colony Forming Unit-
Fibroblast (CFU-F) assay. Lipoaspirate-derived MSCs, derived from abdominal subcutaneous 
tissue (used as a comparator material, see characterization in fig. S1), thawed, and grown in 
identical medium from p2-p4, demonstrated significantly lower CFU-F activity in the same 
assay (Fig. 1C). HUCPVCs exhibited the ability to differentiate into adipocytes, osteocytes, 
and chondrocytes in vitro (Fig. 1D). One donation from an individual umbilical cord could be 
manufactured into a cell product containing a minimum of 1.04 x108 cells (DMEM+PL 
(DMPL) at initiation: 1.04x108 to 2.97x108; n=3) or min 4.35x108 cells (SMPL at initiation: 
4.25x108 to 24.5x108; n=3) by passage 2. HUCPVCs constitutively expressed the T cell 
inhibitory surface molecules PD-L1 (CD274) and PD-L2 (CD273) (Fig 1E). “Licensing” 
(exposure to inflammatory cytokines) of HUCPVCs with Interferon-gamma (IFN- γ) increased 
the relative fluorescence intensity of CD273 and CD274 (Fig 1E). 
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GMP HUCPVCs are potent T cell inhibitors that do not require a priori licensing by IFN-
gamma 
HUCPVCs exhibited robust inhibition of T cell proliferation. Addition of these MSCs to 
mitogen-stimulated peripheral blood mononuclear cells (PBMCs) in a ratio of 2:1 
PBMCs:HUCPVC inhibited T cell division (Fig. 2A), with an effect still measurable at 8:1 (Fig 
2A). T cell inhibition by HUCPVCs was achieved without licensing). Addition of IFN- γ as a 
single licensing cytokine did not significantly increase the ability of the HUCPVCs to suppress 
T cell proliferation in this assay (Fig. 2B). Licensing of HUCPVCs with multiple cytokines - 
IFN- γ, Interleukin-1-beta (IL-1β), and Tumour necrosis factor-alpha (TNF-α) did not increase 
the ability of HUCPVCs to suppress T cell proliferation compared to unlicensed cells (fig. S2). 
Unlicensed HUCPVCs grown in all 3 GMP compliant media types efficiently suppressed T 
cell proliferation irrespective of whether the complete SM medium was supplemented with AB 
plasma or PL.  
 
GMP HUCPVCs express multiple immune-regulatory and pro-regenerative factors 
HUCPVCs were assessed in the unlicensed and licensed state for the expression of a variety of 
anti-inflammatory and pro-regenerative factors, comparing to lipoaspirate-derived MSCs. Both 
MSC types expressed steady amounts of transcript for TGF-beta with and without licensing 
(raw CT range: 21-24, Fig. 3A). Licensing of MSCs strongly increased the expression of TSG-
6 and IDO (raw CT range: unstimulated 20-23, stimulated 14-16) (Fig. 3, B and C). CD274 
expression was also significantly increased after licensing in HUCPVCs compared to 
lipoaspirate-derived MSCs (Fig. 3D). HUCPVCs significantly upregulated production of 
CXCL8 and VEGF protein after licensing (Fig. 3, E and F). Lipoaspirate-derived MSCs also 
produced increased amounts of CXCL8 and VEGF in response to licensing, although this did 
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not reach significance (Fig. 3, E and F). Both factors are strongly associated with blood vessel 
formation; VEGF is also a strong T cell activation inhibitor. Measurement of MSC-derived 
TGF-beta was not possible in the SM-based medium, as this medium contains TGF-beta as a 
supplement. 
 
Comparative expression of multiple chemokines in the resting and licensed state of 
HUCPVCs and adipose tissue MSCs 
HUCPVCs and MSCs derived from adipose tissue were assessed in the unlicensed and licensed 
state with respect to changes in chemokine expression. Chemokine expression profiles 
associated with an inflammatory state, an anti-inflammatory state, a proangiogenic state 
(chemokines containing the ELR motif), and a potentially angiostatic state (chemokines 
lacking the ELR motif) were assessed using 4 separate analyses. The ELR motif consists of 3 
amino acids, Glu, Leu, Arg, present in a family of chemokines which are potent inducers of 
angiogenic activity (31). 
The heat map in Fig. 4 demonstrates major differences between the MSC types, 
showing anti-inflammatory and proangiogenic properties of HUCPVCs and pro-inflammatory 
and potentially angiostatic activity of the lipoaspirate-derived MSCs. Of note the HUCPVCs 
do not express inflammatory-associated chemokines in either the steady state or after cytokine 
challenge, whereas lipoaspirate-derived MSCs express a suite of potentially inflammatory 
chemokines at rest and then switch to a different inflammatory state after cytokine challenge. 
 
Kidney capsule transplantation in immunodeficient mice 
To begin to evaluate the therapeutic potential of GMP HUCPVCs, experiments were set up to 
firstly examine islet grafts: for this the kidney capsule route was used. All immunodeficient 
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mice were transplanted with a marginal mass of human islets (3000 IEQ/mouse) within four 
weeks of administration of streptozotocin (STZ). Prior to transplant, there were no differences 
in glucose concentrations or weights among groups [glucose: 30.1±1.0 vs. 32.6±1.0 mmol/L 
(mean ± SEM), weight: 26.4± 0.5 vs. 25.6 ± 0.6 g, islet transplant group vs. islet+HUCPVCs 
group, respectively (P > 0.05)]. In the pilot experiments transplanting human islets (4000 
IEQ/mouse) within four weeks of administration of STZ, there were no differences in glucose 
concentrations or weights among groups [glucose:  22.7±1.6 vs. 20.8±0.9 vs. 24.1±1.4 mmol/L 
(mean ± SEM), weight: 33.7± 0.5 vs. 29.8± 1.5g vs. 31.9±0.8g, islet transplant vs. 
islet+HUCPVCs vs. islet+Lipo-MSCs (all P > 0.05)]. Tables S1 and S2 show the clinical 
information for the human islet preparations used in these kidney capsule transplant studies, 
including donor characteristics and in vitro static glucose stimulated insulin release (GSIS) and 
oxygen consumption rate (OCR) normalized to DNA.  
 
1:30 IEQ:HUCPVCs in a marginal islet transplant model in immunodeficient mice 
produced optimal long-term metabolic results  
In initial pilot experiments, 4000 IEQs were transplanted in NOD SCID gamma (NSG) mice 
with or without 1x105 HUCPVCs or Lipoaspirate-MSCs. Lipoaspirate-MSCs did not enhance 
islet function (fig. S3A). In mice receiving islets alone or islets plus HUCPVCs, glycemic 
control was tighter at 6 weeks post-transplant (fig. S3B, tables S1 and S2 – islet preparation 1). 
Stimulated blood glucose concentrations were below counterpart control NSG mice that had 
not received STZ [with normal glucose tolerance (NGT), fig. S3B]. Therefore, a marginal islet 
mass approach was adopted and subsequent experiments were performed using 3000 IEQs per 
mouse via the kidney capsule route, and only HUCPVCs were tested further for their ability to 
optimize islet transplant (tables S1 and S2 – islet preparation 2).   
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Mice receiving 3000 IEQs plus 90,000 HUCPVCs (1:30 IEQ:HUCPVCs) reached 
“cured” blood glucose concentrations post-transplant (defined as non-fasted plasma glucose 
<11 mmol/L after STZ and transplant) faster compared to mice receiving grafts of islets alone 
or lower numbers of HUCPVCs (Fig. 5A, post-hoc tests P < 0.001). The average number of 
days to cure was 16.0±1.7, 12.0±2.6, 3.0±0.4, and 9.0±3.6 for mice receiving grafts of 1:0, 
1:10, 1:30, and 1:50 IEQ: HUCPVCs, respectively. 
At 2.8 weeks post-transplant, glucose control as determined in the intra-peritoneal 
glucose tolerance test (IPGTT) was superior in mice transplanted with islets plus HUCPVCs, 
with no statistical significance between the islet plus HUCPVCs groups (Fig. 5B; Table 1). At 
7 weeks post-transplant, glucose control determined by IPGTT was superior with 3000 islets 
plus 90,000 HUCPVCs (ratio of 1:30 IEQ:HUCPVCs), with no significant difference between 
grafts with islets alone and other ratios of HUCPVCs (Fig. 5C; Table 1). At 12 weeks post-
transplant, the tightest glycemic control was seen in mice receiving 1:30 and 1:50 
IEQ:HUCPVCs, with no difference in those receiving islets alone and 1:10 IEQ:HUCPVCs 
(Fig. 5D). By 16 weeks, the best glycemic control was seen in mice transplanted with 1:30 
IEQ:HUCPVCs (Fig. 5E). On 2-way ANOVA analysis there was an effect of time post-
transplant on the integrated glucose response, with an interaction between time post-transplant 
and numbers of HUCPVCs received. However, post-hoc analyses examining the effect of time 
(from 2.8 to 16 weeks) on graft function found no deterioration with the 1:30 IEQ:HUCPVCs 
grafts.  
The ratios of circulating C-peptide to glucose concentration at 60 minutes concurred 
with these observations and were elevated in mice transplanted with 1: 30 IEQ:HUCPVCs at 
12 and 16 weeks (Fig. 5F and G). Control experiments were performed in STZ-treated mice 
receiving Matrigel alone versus HUCPVCs in Matrigel. Glucose concentrations did not fully 
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normalize in either group, however glucose concentrations were lower in mice receiving 
HUCPVCs in Matrigel versus Matrigel alone (fig. S4). 
 
Confirmatory studies demonstrate hyperglycemia after removal of islet grafts  
After 16 weeks, mice with transplants (n=5) underwent left nephrectomies to remove islet 
grafts; these mice reverted to diabetes and blood glucose concentrations increased from 5.0±0.1 
mmol/L on the day of surgery to hyperglycemia (18.8±1 mmol/L) three days post-surgery. 
These results confirmed that the normoglycemic state was a consequence of islet transplant 
rather than the regeneration of mouse islets in the pancreas (fig. S5).  
 
Vessel density in islet graft was increased with islets co-transplanted with HUCPVCs 
To determine whether vascularization was increased in the grafts where islets were co-
transplanted with HUCPVCs, vessel density was quantified within the islet grafts. Vessel 
density was increased in islet grafts co-transplanted with 3000 islets plus HUCPVCs, in a ratio 
of 1:10 and 1:50 (Fig. 6, A and B), as compared to grafts of islets alone. Results were confirmed 
using immunofluorescence analysis with a further endothelial marker to ERG (fig. S6). Grafts 
with 4000 islets and 1x105 HUCPVCs were also examined and demonstrated non-significantly 
greater vessel density in these grafts with HUCPVCs (p = 0.07, fig. S7). 
 
In vivo syngeneic, allogeneic, and human islet transplants in mice via HPV 
To examine the metabolic function of islets with HUCPVCs, transplant experiments were done 
via the hepatic portal vein into the liver, emulating the clinical route used in man. Islet 
transplantation in man involves transplantation of islets from a donor with a different tissue 
and blood type to the recipient and islets may be rejected in part secondary to alloimmune 
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mechanisms. To model this allogeneic transplant in mice, immunocompetent C57Bl/6 mice 
may be transplanted with islets from Balb/C mice, eliciting a brisk rejection of transplanted 
Balb/C islets. A marginal Balb/C islet mass (500 IEQs/mouse) was used and IEQ:HUCPVCs 
ratios of 1:0, 1:90, 1:150, and 1:210 were explored. In a second experiment a curative mass 
was used (900 IEQ/mouse), comparing IEQ:HUCPVCs ratios of 1:0 versus 1:150.  To 
investigate syngeneic transplant, immunocompetent C57Bl/6 mice were transplanted with 
islets from C57Bl/6 mice within 9 days of administration of STZ. Finally, immunodeficient 
NSG mice were transplanted with human islets from a single islet isolation (table S1 and S2; 
donor 3).   
Prior to transplant, all groups of mice had established diabetes with blood glucose 
readings > 17 mmol/L and there were no differences in glucose concentrations or weights 
between treatment groups (P > 0.05, table S3). There was no evidence of cellular mediated 
rejection in the liver after transplantation of 150,000 HUCPVCs with mouse islets via the 
HPV of immunocompetent C57Bl/6 mice at day 1 and day 8 post-transplantation (fig. S8).  
 
1:90 and 1:150 IEQs:HUCPVCs via the HPV produced optimal metabolic results in short-
term allogeneic experiments  
Using a marginal islet mass approach, transplant of 500 IEQs per mouse±HUCPVCs was tested 
to assess optimized islet function up to 10 days post-transplant. Islets from a BALb/C mouse 
were transplanted into a C57Bl/6 mouse via the HPV at IEQ:HUCPVCs ratios of 1:0, 1:30, 
1:90, and 1:150. Blood glucose concentrations decreased most in the mice transplanted with 
1:90 and 1:150 IEQ:HUCPVCs (Fig. 7A), although this decrease did not reach statistical 
significance. Blood glucose concentrations did not change in mice transplanted with islets 
alone. Blood glucose concentrations reached a nadir at day 2-3 post-transplant but glycemic 
control deteriorated in all groups by day 8 post-transplant, reflecting rejection of the islet grafts. 
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The experiments were repeated with 900 IEQs per mouse±HUCPVCs in a ratio of 1:150 versus 
900 islets alone in an attempt to cure the mouse of diabetes and to ascertain whether HUCPVCs 
ameliorated or delayed graft rejection. Five of 6 mice receiving HUCPVCs were cured of 
diabetes at day 1 versus 3 out of 7 mice receiving islets alone. There was a slower increment 
in blood glucose concentrations in all mice receiving islets plus HUCPVCs, consistent with 
delayed graft rejection (Fig 7B). Frank hyperglycemia (plasma glucose ≥13 mmol/L) was 
evident by day 5 in all mice receiving islets alone whereas hyperglycemia in the mice receiving 
islets plus HUCPVCs was delayed until day 8 (P = 0.04). 
 
1:150 IEQ:HUCPVC transplanted via the HPV in an immunocompetent syngeneic model 
produced optimal metabolic results in long-term experiments  
Using a marginal islet mass approach, 500 IEQs were implanted per mouse with or without 
HUCPVCs to assess optimized islet function up to 6 weeks post-transplant. Islets from C57Bl/6 
mice were transplanted into C57Bl/6 recipient mice via the HPV in the following 
IEQ:HUCPVCs ratios: 1:0, 1:90, 1:150, and 1:210. 
Blood glucose concentrations decreased in the mice transplanted with 1:150 
IEQ:HUCPVCs, and these mice maintained the tightest glycemic control over the 6 week 
duration of the experiment (Fig. 7C). The mice receiving an IEQ:HUCPVC ratio of 1:150 had 
the greatest insulin:glucose concentrations after IPGTT 6 weeks post-transplant (Fig. 7D). All 
mice (n=8) transplanted with 1:150 IEQ:HUCPVCs were cured from their diabetes versus n=3-
4 mice in all other groups (χ2=7.5; p=0.02). Liver function tests at cull were normal in both 
groups with no significant differences between the groups (fig. S9).  
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1:150 human IEQ:HUCPVC transplanted via the HPV in an immunodeficient mouse model 
cured diabetes and led to long-term cure rates  
Using a marginal islet mass approach, 700 human IEQs per mouse with or without HUCPVCs 
in a ratio of 1:150 IEQ:HUCPVCs were transplanted to determine ability to cure diabetes and 
maintain cure for 7 weeks after islet transplantation. Blood glucose concentrations decreased 
significantly in the mice transplanted with 1:150 IEQ:HUCPVCs and diabetes in mice was 
cured, maintaining normoglycemia for the 7 week duration of the experiment (Fig. 8).  At the 
end of the experiment, the average glucose concentration in mice receiving islet-only 
transplants vs. islet ±HUCPVCs was 34.7±7.2 vs. 11.2±2.6 mmol/L (mean±SEM, P < 0.01). 
Six out of 8 mice transplanted with 1:150 IEQ:HUCPVCs were cured from their diabetes 
versus n=0 mice in the group transplanted with islets without HUCPVCs (χ2=6; p<0.01).  
 
DISCUSSION  
Here we demonstrated that GMP compliant HUCPVCs produced in xeno-free conditions are 
capable of rapid post-thaw in vitro expansion at passage 2-4, with stability of phenotype 
throughout passages. HUCPVCs exhibit immunosuppressive properties in the non-licensed 
state. We also demonstrate that these specific MSCs are distinct from those derived from 
lipoaspirate, with anti-inflammatory and pro-regenerative properties in the licensed state. In 
vivo, using a kidney capsule route of administration, the ratio of HUCPVCs to human islets, 
which demonstrated optimal metabolic function  (32), was 30 to 1. Transplanting grafts of this 
ratio led to rapid control of glucose by 3 days post-transplant and superior graft function at 
both early (2.7 weeks post-transplant) and later stages (7, 12, and 16 weeks post-transplant). 
After 100 days, defined as long-term in such models (33), there was no evidence of graft 
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dysfunction and there was increased vascular density in grafts containing HUCPVCs versus 
grafts of islets alone.  
In immunocompetent mice, we demonstrated that these human umbilical cord MSCs 
did not elicit an immune response, consistent with other studies (34) and providing proof of 
concept of using this model in syngeneic islet transplant experiments in the absence of 
immunosuppression. Transplanting mouse islets with HUCPVCs (1:150 IEQ:HUCPVCs) by 
the HPV route in immunocompetent mouse models produced optimal glycemic results in the 
short and longer term (up to 6 weeks after transplant). Previous experiments had not 
systematically examined the dose of MSCs relative to islets for efficacy regarding glycemic 
control. We further confirmed that transplantation of human islets with HUCPVCs, 
transplanted via the HPV route, in immunodeficient mice led to a cure of diabetes in these mice 
which was maintained for the 7-week duration of the experiment without evidence of long-
term adverse effects on the liver.  
The ease of procurement of umbilical cord tissue over other tissue sources, ability to 
rapidly expand this MSC population, and stable phenotype makes this an ideal MSC source for 
off-the-shelf banking and use (35). MSCs used in these experiments were assayed after a 
cryopreservation step at p1, thawing cells in xeno-free GMP medium before use, with 
demonstrable in vivo function. The functional utility of thawed HUCPVCs used immediately 
following cryopreservation has also recently been demonstrated (36), contrasting with prior 
reports suggesting it is necessary to culture bone marrow mesenchymal cells after 
cryopreservation to restore their immune-regulatory properties (37; 38). In contrast to our 
findings, some groups have demonstrated that MSCs derived from adipose tissue have a 
beneficial effect on islet transplantation (39); the source of fat as well as other donor factors 
may be critical. 
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The ability to suppress T cell activation and express TGF-beta in the non-stimulated 
state has not previously been described for MSCs (40; 41) and is beneficial, along with the 
ability to upregulate pro-regenerative factors when induced by inflammation. TSG-6 
expression has been recently shown to play a central role in MSC suppression of inflammation 
in vivo (42) and the HUCPVCs used here highly upregulated this factor in response to 
inflammation. At 24 to 48 hours post-islet transplant there is marked inflammation in the liver 
(11; 43; 44) which compromises islet survival and engraftment. MSCs may exert protective 
effects by promoting angiogenesis and immunomodulation (45; 46). With time, as 
inflammation becomes quiescent, vascularization of islets takes place and is largely complete 
within 4 to 6 weeks.  
Autologous bmMSC trials are underway in different disease areas including patients 
with Type 1 diabetes (47). Furthermore in certain diseases including graft versus host disease 
(48-53), critical limb ischemia (54; 55), and acute myocardial infarction (56), allogeneic 
bmMSCs have been administered with considerable success, although no Phase III trials have 
been reported. No center has performed randomized controlled clinical trials using allogeneic 
MSCs in patients with Type 1 diabetes undergoing islet transplantation. One open label, 
randomized, pilot study in humans transplanting autologous bone marrow mononuclear cells 
(bmMNC) with a small proportion of Wharton’s Jelly-derived cells that had not been 
phenotyped demonstrated evidence of preservation of graft function (23). No conclusions with 
respect to the effect of the mesenchymal cell population can be reached from these bmMNC 
studies, although such studies illustrate the clinical utility of MSCs for transplantation in Type 
1 diabetes.  
There are several small studies that have examined autologous bmMSCs in Type 1 
diabetes and in animal models of islet transplantation. Many studies used an IEQ:MSC ratio of 
approximately 1:10 or lower (57-59), showing modest effects on graft function but pronounced 
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effects on graft vascularity. Although dosage experiments are difficult to perform and interpret 
in clinical practice, the optimum ratio that we demonstrate is in excess of previously reported 
ratios and in concord with MSC numbers used in primate studies (18). In our experiments, an 
IEQ:MSC dose of 1:10 did not yield sustained effects on graft function. It is of interest that the 
largest quantity of MSCs in our study did not demonstrate the greatest benefit in terms of graft 
function, indicating the possibility of a plateau effect with MSCs that may be tissue source 
dependent. This further emphasizes the importance of our dose response studies. The 
experimental route of human islet transplantation under the kidney capsule was selected for 
experiments in immunodeficient mice because islets remain at the site of delivery, enabling 
quantification of vasculogenesis; we confirmed vascular density using two different 
methodologies. Islet delivery via the hepatic portal route more closely reflects the clinical 
scenario, however the islets tend to disseminate throughout the liver as well as the systemic 
circulation and it is therefore not possible to quantify vasculogenesis. Our HPV studies in 
immunocompetent mouse models using mouse islets, as well as in immunodeficient mouse 
models using human islets, inform the optimal ratio of islets to HUCPVCs to use via the hepatic 
portal route of delivery in man and we further confirmed longevity of graft function to 7 weeks 
in these models using a separate isolation of islets.    
The fate of MSCs post-transplant is largely unknown; tracking cells to determine 
whether they engraft or differentiate is necessary but remains a limitation of the present work. 
We presented extensive data regarding expression of inflammatory response modifying factors 
by the MSCs, which associated with improved transplant outcome. However, the effects of 
transplanted MSCs on recruitment and modification of other host cell populations in the 
transplant setting is not yet determined. Immune modulation and angiogenic factor expression 
is strongly upregulated in vitro after licensing with cytokines, and repeating our observations 
with licensed MSCs could aid interpretation of the therapeutic relevance of the many factors 
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expressed by the MSC. Here we examined both grafts formulated in Matrigel and transplanted 
into the kidney and grafts introduced to the liver via the HPV, the route used in humans. We 
cannot robustly compare the numbers of HUCPVCs used successfully in this study to numbers 
of bmMSCs used in other published studies due to differences in the experimental route of 
transplant. Other limitations include that the HUCPVC studies were not carried out with 
immunosuppression in immunocompetent recipients and that the experiments were confined 
to small animal models using only male animals. Dose escalation studies are required to fully 
evaluate the effect of HUCPVCs with immunosuppression in man. 
An important aspect of these studies is that human GMP grade HUCPVCs at passage 3 
and human islets were used in immunodeficient mouse models; furthermore, a single large islet 
donation was used for the main transplant experiments via the kidney capsule and the HPV 
route in the mice, facilitating interpretation of the findings. It is well recognized that there is 
considerable donor heterogeneity in islet samples. Thus, such studies are difficult to perform 
in animal models with respect to timing.  
The findings of this study have major clinical implications. At present, subjects with Type 1 
diabetes need to receive islets from at least two donor pancreata to improve glycemic control; 
there is a shortage of suitable donor pancreata, and attrition in graft function is seen over time, 
likely secondary to loss of beta cells through autoimmune, alloimmune, and inflammatory 
mechanisms. Furthermore, over 60% of islets are lost in the first 24 to 48 hours post-transplant 
(11; 43; 44). Our study demonstrates the mechanism of action of GMP grade HUCPVCs in 
vitro and positive effects in vivo on graft function in vivo. These results lay the foundation for 
future safety studies in animal models, which should include the tracking of MSCs by state-of-
the-art molecular techniques and an assessment of long-term safety and tumorigenesis. With 
such data it will be possible to proceed with randomized controlled clinical trials in man.  
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MATERIALS AND METHODS 
Study design 
The purpose of this study was to explore whether MSCs improved islet transplantation 
outcomes, and to elucidate the mechanism of action. We carried out islet transplantation 
experiments using the kidney capsule route to examine the islet graft in its entirety, as well as 
transplantation via the HPV to emulate the transplant route used clinically. MSCs manufactured 
using GMP compliant methods from human umbilical cord and adipose tissue were extensively 
characterized at a phenotypic and molecular level, including expression of inflammation and 
angiogenesis-modulating chemokines and cytokines. 
Human islets were transplanted into immunodeficient mouse models and mouse islets 
were transplanted in immunocompetent mouse models. The optimal ratio of islets to 
HUCPVCs was determined. Sample sizes were determined on the basis of prior experience 
with similar studies and pilot experiments. All mice used were males to eliminate any potential 
confounding influences of differences in engraftment secondary to gender. All mice were 
randomly assigned to treatment groups and all analysis performed blinded to treatment 
condition. No surviving animals were excluded from analysis and no outliers were excluded. 
The number of biologic replicates is specified in the figure legends.  
 
Materials 
All human tissue (donated material) was fully consented for use in research, and ethical 
committee approval was obtained [Pancreatic islets ethics approval (SNBTS) REC reference: 
13/NW/0105 IRAS project ID: 124650 and sample governance 14-29v2 and University of 
Alberta Research Ethics Board, Pro00013094]. The use of umbilical cord material was 
governed under ethics approval (Edinburgh Reproductive Tissue Biobank (ERTBB)-097 and 
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NHS Greater Glasgow & Clyde Project REC reference GN14NN406). All blood samples used 
in immune response assays were governed under the SNBTS sample governance committee 
approval process permission 14-02. 
 
Generation of GMP grade HUCPVC 
HUCPVC were generated for use in this study under a collaborative research agreement with 
Tissue Regeneration Therapeutics Inc. Methodology was based on published methods for 
establishment of HUCPVC from Wharton’s Jelly (25) with modifications to use commercially 
available xeno-free medium with or without clinical grade AB plasma or platelet lysate 
supplements. Briefly, umbilical cords were aseptically dissected as described (26), and the 
Wharton’s Jelly (WJ) was placed in culture. The cells are described as HUCPVCs as the WJ 
was harvested from the clearly distinguished tunica media of the 3 vessels of the cord [as 
discussed in Davies et al. (30)]. The cells are thus perivascular stromal cells, but not pericytes. 
Umbilical cord of 6-10 cm yielded approximately 2 ml of dissected material that was used to 
seed one 175 cm2 flask. Explants were cultured in DMEM (Gibco), Heparin (Leo Labs) at a 
final concentration of 2 IU/mL, 1x Non-essential Amino Acids (Gibco) supplemented with 
25% human platelet lysate (PL) in Corning Cell Bind flasks with no additional substrate. Once 
the cells had reached 80-90% confluence the adherent MSCs were recovered with a 10 min 
incubation at 37°C with 10 mL of 1 x TryplE (Gibco). To remove cell debris the material was 
passed through a 100 µm cell strainer (Falcon). The cells were counted using a haemocytometer 
and designated as passage 1 (for standardization purposes; the growth and time in culture for 
each cell line was recorded according to doubling rate). These MSCs were then cryopreserved 
at 1x106 / vial in Cryostor (CS10, Sigma Ltd). Later in the study a further 3 cell isolates cells 
were grown to p1 in StemMACS medium supplemented with 25% PL instead of the DMEM-
based medium. Thawed cells were washed once in StemMACS medium and re-cultured at 
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3000 cells/cm2 in fresh flasks for up to 4 passages. Cells were cultivated from passage 2 to 
passage 4 in 3 GMP complaint xeno-free media – StemMACS MSC XF (SM) (Miltenyi 
Biotec), Stem MACS MSC XF supplemented with 25% human Platelet Lysate (SM PL), or 
Stem MACS MSC XF supplemented with 10% human AB plasma (SM AB). 
 
Preparation of mouse models prior to islet transplantation experiments  
All animal procedures complied with Home Office Guidance on the operation of the Animals 
(Scientific Procedures) Act 1986, and conformed to local ethical requirements of the University 
of Edinburgh. Male NSG (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ /NOD SCID Gamma) mice were 
used to establish the human islet transplant models, male C57Bl/6 mice were used to establish 
syngeneic and allogeneic islet transplant models. Animals (n=8-10/group) were rendered 
hyperglycemic at 16-17 weeks old by administration of 160-180 mg/kg i.p. STZ (Sigma-
Aldrich) in ice cold acetate buffer, pH 4.5, following a 4-hour fast. Daily tail blood glucose 
measurements were taken using a glucometer (One Touch Verio, LifeScan). Mice were classed 
as hyperglycemic if their non-fasted glucose concentrations were ≥20 mmol/L for two 
consecutive days. Once diabetes was confirmed, daily subcutaneous injections (0.5-2.5U) of 
insulin glargine (Lantus, Sanofi) were administered, until the day prior to islet transplantation. 
All islet transplantations took place within 4 weeks of administration of STZ.  
 
Procurement and preparation of human islets and HUCPVCs 
Three human islet preparations were isolated from donor pancreata by the Islet isolation 
laboratories using the Edmonton Protocol (2). In the clinical islet isolation laboratory (SNBTS) 
those islet preparations that did not meet clinical release criteria because of numbers (<200,000 
IEQs) and that were consented for research purposes were utilized in the laboratory. Due to the 
inherent heterogeneity of donor islet preparations, one large islet preparation was used in the 
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longitudinal NSG mouse experiments with 3000 IEQs transplanted via the kidney capsule route 
as described (Table S1 and S2). Prior to this one preparation had been used in pilot experiments 
that utilized 4000 IEQs transplanted via the kidney capsule route. Similarly in the HPV 
transplants in NSG mice, one large islet preparation from a single islet isolation (donor 
preparation 3; Alberta Diabetes Institute, Islet Core Facility) was transplanted. Upon receipt of 
islets by the research lab, the islets were cultured in CMRL-1066 media (Mediatech), 
supplemented with 10% FCS (v/v, Scientific Laboratory Supplies), heparin (10 U/ml, Leo 
Pharma), penicillin/streptomycin (100 U/ml and 100 µg/ml respectively, Gibco), and 2mM L-
Glutamine (Gibco), at 22°C/5% CO2. All HUCPVCs for in vivo use were thawed from the p1 
stock and grown to p3 for use. Cells were cultured in StemMACS (Miltenyi Biotech), and 5% 
Human PL. 
 
Islet transplantation in immunodeficient NSG mouse model via kidney capsule route 
Islet transplantation was carried out at 4000 IEQs initially ±1x105 Lipoaspirate MSC or 
HUCPVC with relevant control groups in the initial studies (fig. S1). Subsequently a marginal 
mass model using 3000 IEQs were transplanted with 3 ranges of HUCPVCs (ratios: 1:10, 1:30, 
1:50) with parallel control groups including with islets alone, matrigel and HUCPVCs plus 
matrigel (6 groups). 
In all co-transplantation experiments of MSC plus islets, both islets and HUCPVCs 
were placed into 0.5ml eppendorf tubes in co-culture for an hour at room temperature before 
transplant. Excess medium was drawn off to leave an islet pellet to which 10-20µl of ice cold 
matrigel (reduced-growth factor, Corning) was added. The islet-matrigel solution was drawn 
up into PE50 tubing just prior to transplant. 
All mice were 20-21 weeks old at the time of transplant. Mice were anaesthetized using 
isoflurane (1.5-3%), the left kidney was exposed under aseptic conditions and the matrigel 
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(±islets±HUCPVCs) transplanted under the left kidney capsule. The wound was sutured and 
clipped before recovery. Control experiments were performed at the same time in the same 
cohorts of mice. 
 
In vivo assessment of efficacy of HUCPVCs in islet engraftment and function in an 
immunodeficient NSG mouse model and immunocompetent C57Bl/6 mouse model 
The function of the islet plus MSC grafts were assessed with an IPGTT. At 2.7, 7, 12 and 16 
weeks post-transplantation under the kidney capsule. NSG mice were fasted overnight and, 
following a basal tail blood glucose reading, received 2g glucose/kg fasted body mass by i.p 
injection. Glucose measurements were then taken at 15, 30, 60, 90, and 120 min post-glucose 
injection. A blood sample was taken at the 60 min time point (into EDTA) for stimulated 
plasma C-peptide analysis. At the 16-week IPGTT further blood samples were also taken at 0 
min and 120 min time points. IPGTTs were similarly carried out following transplantation of 
C57Bl/6 mouse islets via the HPV route into C57Bl/6 mice. At 6 weeks post-transplant, a blood 
sample was taken fasting and at the 60 min time point (into EDTA) for stimulated plasma 
insulin analysis. 
 
Unilateral left nephrectomy as confirmation of insulin-secreting function of islets ± 
HUCPVCs engrafted kidney 
The left kidneys of half the mice (receiving 1:30 or 1:50 IEQ:HUCPVCs at transplant) were 
removed via laparotomy at day 101, defined as the point of long-term engraftment (60). These 
mice were followed for a further five days to confirm the return of hyperglycemia.  
All mice were culled following the IPGTT at 16 weeks and histology, including assessment of 
vascular density, performed. 
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Mouse islet isolation and culture 
Pancreatic islets were isolated from C57BL/6, BALB/c mice (9 weeks old, 20-22 g) by a 
collagenase digestion method (61). The islets (250 islet/mL) were cultured free floating (37-C, 
5% CO2) in RPMI medium 1640 (Bio-Whittaker, Walkersville, MD) supplemented with L-
glutamine (Sigma), penicillin-streptomycin (1000 U/mLY10 mg/mL; Sigma) and 10% 
(vol/vol) fetal calf serum (HyClone, Celbio, Logan, UT) for up to 12 hours before the 
transplant. Islet purity was ≥90%. 
 
Transplantation experiments via the HPV route in immunocompetent mice  
All mice were 12-14 weeks old at the time of transplant. Animals were anaesthetized using 
isoflurane (1.5-3%), and HPV transplant was performed following a midline laparotomy 
exposing the HPV with subsequent injection of islets into the vein using a 27G needle followed 
by control of bleeding and resuturing of the skin wound.  
 
Islets ± HUCPVC transplant experiments in mice via the HPV route 
HUCPVCs (n=150,000) plus islets versus control experiments with islets alone 
(500IEQ/mouse) were injected into C57Bl/6 mice via the HPV route.  
Mice were sacrificed at day 3 and day 8 (n=8/group). The livers were removed, step sectioned 
(5µm) and H and E stained for an immune infiltrate and quantified using the Nikon Eclipse 
TE2000-S microscope.  
 
Allogeneic islet ± HUCPVCs transplants from BALB/c into C57Bl/6 mice 
Allogeneic experiments used islets from BALB/c mice transplanted into C57Bl/6 mice via the 
HPV route with IEQ: HUCPVC ratio of 1:0, 1:30, 1:90 and 1:150 (n=6/group; n=500 IEQs per 
mouse). Mice were sacrificed at day 10 post-transplant.  
24 
 
In a second series of experiments, mice were transplanted with IEQ: HUCPVC ratio of 1:0 and 
1:150 (n=8/group; 900 IEQs per mouse). Mice were sacrificed at day 21 post-transplant.  
 
Syngeneic islet ± HUCPVCs transplants from C57Bl/6 donor and recipients 
Syngeneic experiments used C57Bl/6 mice as donors and recipients with an IEQ: HUCPVC 
ratio of 1:0, 1:90 and 1:150 and 1:210 (n=7-9/group). Mice were sacrificed at 6 weeks post-
transplant. At cull bloods were analyzed for liver function tests [aspartate aminotransferase 
(AST), alanine aminotransferase (ALT) and albumin]. 
 
Statistical analysis 
Data was tested for normality and transformations were applied as appropriate. The integrated 
area under the curve (AUC) for glucose was calculated by the trapezoid rule (62). Glucose 
AUC measurements, time to cure diabetes with IEQ± HUCPVCs, 60-minute C-peptide:glucose 
ratios, and graft vessel densities were compared by ANOVA with post-hoc testing between 
groups. Gene expression and protein concentrations were examined by ANOVA, or in the case 
of two data sets, unpaired t-tests or Mann Whitney U test as specified. Statistical significance 
was taken as p<0.05. Group sizes of n=6 for the mouse studies (59) demonstrated 80% power 
to detect a 20% difference in response at the 95% level of significance.  
 
 
 
 
 
 
25 
 
Supplementary Materials 
Materials and Methods 
Fig. S1. Characterization of lipoaspirate-derived MSCs in vitro. 
Fig. S2. Inhibition of T cell proliferation by HUCPVC. 
Fig. S3. Characterization of lipoaspirate-derived MSCs in vivo. 
Fig. S4. AUC glucose 6 weeks after transplant. 
Fig. S5. Glucose concentrations following removal of kidney islet graft by nephrectomy. 
Fig. S6. Immunofluorescence analysis with endothelial marker ERG. 
Fig. S7. Vessel Density in islet grafts with and without HUCPVCs. 
Fig. S8. Histological assessment of cell infiltrate into liver after syngeneic islet grafts 
 ±HUCPVC. 
Fig. S9. Liver function 6 weeks after transplant. 
Table S1. Human islet preparation and associated clinical characteristics. 
Table S2. GSIS and OCR of islet preparations. 
Table S3. Glucose Concentrations and Weights Prior to Surgery. 
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Figure legends 
 
Fig. 1. HUCPVCs grown in different GMP compliant media. (A) Representative 
phenotypic analysis of HUCPVCs grown in GM-compliant medium (SMAB). HUCPVCs 
passage 3, baseline fluorescence set using matched isotype controls. Right: Percentage of 
HUCPVCs expressing a CD14-CD45-CD73+CD90+CD105+ phenotype across 3 serial 
passages (p2-p4). n = 3 individual donations. (B) HUCPVCs grown in different GMP media 
across 3 passages (p2-p4) from n = 5 donated samples of umbilical cord. Mean doubling time 
± SEM (days) using different GMP compliant media. No significant differences between media 
used to expand cell lines 2-way Anova with Tukey’s multiple comparison test. P ranges from 
0.22 to 0.99. (C) Colony forming unit scores for HUCPVCs and lipoaspirate MSCs grown in 
different GMP compliant media from 3 different tissue donations across 3 passages (p2-p4) 
with numbers of colonies obtained from plating 10 cells/cm2 in CFU-F medium quantified 
mean ± SEM shown, CFU-F significantly higher in HUCPVC than lipoaspirate cells (p<0.01) 
paired T-test in all media tested. (D) Differentiation of HUCPVCs to adipocytes, osteocytes, 
and chondrocytes. Samples were stained with Oil Red-O (adipo), Alazarin Red (osteo), or 
Safranin O (chondro) as described (63). Bright field microscopy magnification 40x. (E) 
Analysis of PD-L2 (CD273) and PD-L1 (CD274) expression on HUCPVCs with and without 
licensing. Light grey peak /green outline– isotype control; grey peak/blue outline – unlicensed; 
white peak licensed. SM – StemMACS, SMAB – SM + AB plasma, SMPL – SM + platelet 
lysate; CFU-F – Colony forming unit-fibroblasts.   
 
 
Fig. 2. Inhibition of T cell proliferation and requirement for IFN-γ licensing for 
HUCPVCs to mediate this effect. (A) Representative dye dilution results measuring 
inhibition of T cell proliferation by HUCPVCs. HUCPVC were grown in SMAB, assayed at 
p4, and cultured with Ef670-stained PBMCs; ratios are PBMC:HUCPVC at outset of culture. 
PHA: phytohemagglutinin. (B) Inhibition of T cell proliferation with and without IFN-γ 
licensing. Comparative measurement of inhibitory effects was made by comparing the 
percentage of T cells remaining in the undivided peak after activation with or without titrated 
amounts of MSCs. Mean±SD of 3 different HUCPVC lines grown in SM PL, ratios are 
PBMC:HUCPVC. (No significant differences between licensed and unlicensed groups at each 
concentration, paired T-test).  
 
Fig. 3. Gene expression and protein production by resting and licensed MSCs. (A) 
TGFβ, (B) CD274, (C) IDO, and (D) TSG6 gene expression in resting and licensed MSCs 
from lipoaspirate (blue) and HUCPVCs (red), measured by qRT PCR and expressed as 2(-ΔCT) 
against expression of RPLP0. Means ± SEM n=3 donors, MSC at passage 3. * P<0.05, ** 
P<0.01. Where plain bars absent, gene expression was lower limit of detection and are not 
included in measurement of significance. (E) CXCL8 and (F) VEGF production by resting 
(plain bars) and licensed (hatched bars) MSCs from liposaspirate (blue) and HUCPVCs (red) 
measured by Luminex 100, in pg/ml. Means±SEM n=3 donors, HUCPVCs and MSCs at 
passage 3. Protein measurements shown net of background measurement of analyte in culture 
medium alone.  
 
Fig. 4. Chemokine expression by resting and licensed Lipo-MSCs and HUCPVC. The 
expression of inflammatory, ELR+ve and ELR-ve chemokines by resting (-) and licensed (+) 
MSCs from Lipo-MSC (adipose) and HUCPVCs (umbilical cord) were measured by RT2 
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Profiler PCR Arrays. The expression of anti-inflammatory genes was measured using qRT PCR 
as indicated. All samples were run at the same time on the same plate. In each case, the average  
2(-ΔCT) is plotted and heatmaps were generated using Heatmapper software 
(http://www2.heatmapper.ca/). Each group of genes was analyzed separately. Genes are 
clustered using the single linkage method. n>3<6 donors, HUCPVC /MSCs at passage 3. 
(Expression of CD274, TSG-6, IDO, and TGF-beta same samples as Fig 3.A) 
 
Fig. 5. Time to cure diabetes with IPGTTs in NSG mice receiving 3000 IEQs and 
HUCPVCs. (A) All mice were transplanted with 3000 IEQs plus different ratios of 
IEQ:HUCPVCs (1:0, 1:10, 1:30, and 1:50). Time to normoglycemia (non-fasted glucose <11.0 
mmol/L) was determined. Tail vein sampling for glucose concentrations (mmol/L) during 
IPGTT (2g/kg) was done at 0, 15, 30, 60, 90 and 120 minutes following IPGTT. Stimulated C-
peptide concentrations (pmol/L) were sampled at 60 mins post IPGTT. Glucose concentrations 
at (B) 2.8 weeks, (C) 7 weeks, (D) 12 weeks, and (E) 16 weeks after islet transplant. Stimulated 
C-peptide concentration (pmol/L) divided by glucose concentration (mmol/L) at (F) 12 weeks 
and (G) 16 weeks. N=6-8 mice/group. Data presented as Mean±SEM. See Table 1 for 
additional information. Black bar: 3000 IEQs alone; red bar: 1:10 ratio of IEQ: HUCPVCs; red 
horizontal lined bar: 1:30 ratio of IEQ: HUCPVCs; red vertical lined bar: 1:50 ratio of IEQ: 
HUCPVCs. Post-hoc analyses for significant differences between ratios of IEQ: HUCPVCs 
are denoted: a -1:0 vs. 1:10; b – 1:0 vs. 1:30; c -1:0 vs. 1:50; d - 1:10 vs. 1:30; e - 1:10 vs. 1:50; 
f – 1:30 vs. 1:50.  
 
Fig. 6. Vessel density in islet grafts implanted under kidney capsule at 16 weeks post- 
transplant. Diabetic NSG mice were transplanted with 3000 IEQs±HUCPVCs 
(IEQ:HUCPVCs of 1:0, 1:10, 1:30, and 1:50). Serial sections (5 µm) in n=5 mice per group 
were cut through the entire islet graft below the kidney capsule and vessel density associated 
with the islet graft was quantified. (A) Vessel density at 16 weeks post-transplant; Data 
presented as Mean±SEM. (B) Immunofluorescence image of a representative section showing 
vessel quantification in an islet graft. Endothelial cells (Isolectin B4) and mature vessels (anti-
smooth muscle alpha-actin antibody) were identified by immunostaining. Black bar: 3000 IEQs 
alone; red bar: 1:10 ratio of IEQ: HUCPVCs; red horizontal lined bar: 1:30 ratio of IEQ: 
HUCPVCs; red vertical lined bar: 1:50 ratio of IEQ: HUCPVCs. Post-hoc analyses for 
significant differences between ratios of IEQ: HUCPVCs are denoted: a -1:0 vs. 1:10; b – 1:0 
vs. 1:30; c -1:0 vs. 1:50; d - 1:10 vs. 1:30; e - 1:10 vs. 1:50; f – 1:30 vs. 1:50.  
 
Fig. 7. Blood glucose concentrations after islet transplant ±HUCPVCs in mismatch 
(allogeneic) and syngeneic transplants. (A). Immunocompetent C57Bl/6 mice (n=4-6/group) 
were transplanted with allogeneic Balb/C islets (n=500 IEQs) and HUCPVCs (ratios 1:0, 1:30, 
1:90 and 1:150). (p>0.05) Mean values of glucose concentration are shown. (B). Glucose 
concentration over time, comparing islet-only grafts (n=900 IEQs) to IEQ:HUCPVCs (1:150) 
in immunocompetent C57Bl/6 mice transplanted with Balb/C islets (n=8 mice /group). (C). 
Immunocompetent C57Bl/6 mice (n=8/group) were transplanted with syngeneic C57Bl/6 
mouse islets and HUCPVCs (ratios 1:0, 1:90, 1:150, and 1:210). Mean values of glucose 
concentration are shown. Tx: transplant. (D). Stimulated (60 min) insulin concentration 
(pmol/L) post IPGTT divided by glucose concentration (mmol/L) at 6 weeks in 
immunocompetent syngeneic islet transplants. N=8 mice/group. Data presented as 
Mean±SEM. 
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Fig. 8. Blood glucose measurement after human islet ±HUCPVCs transplant in 
immunodeficient mice. Immunodeficient NSG mice (n=8/group) were transplanted with 700 
human islets ± HUCPVCs in a ratio of 1:150 IEQ:HUCPVCs. Mean±SEM values shown; 
difference between groups p<0.01. 
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 Table 1. AUC of glucose concentrations after IPGTT. Data presented as mean±SEM. The 
integrated area under curve of glucose concentrations were calculated during 120 minute IPGTT 
(mmol/Lxmin2) at 2.8, 7, 12 and 16 weeks post islet transplant; N=6-8 mice/group. One way ANOVA 
analyses comparing effect of integrated glucose response with ratio of islets: HUCPVCs transplanted 
under the kidney capsule were compared at separate time intervals. Tx: transplant. Post-hoc analyses 
for significant differences between ratios of islets to HUCPVCs are denoted: a -1:0 vs. 1:10; b – 1:0 vs. 
1:30; c -1:0 vs. 1:50; d - 1:10 vs. 1:30; e - 1:10 vs. 1:50; f – 1:30 vs. 1:50.  
Weeks  
post-Tx 
Islet:HUCPVC 
1:0 
Islet:HUCPVC 
1:10 
Islet:HUCPVC 
1:30 
Islet:HUCPVC 
1:50 
p ANOVA 
 
 
2.8 weeks 
 
970±8 
 
430±20 
 
457±9 
 
457±23 
 
<0.0001a,b,c 
 
7 weeks 
 
902±171 
 
672±35 
 
473±15 
 
691±53 
 
0.02b 
 
12  weeks 
 
1111±123 
 
1218±40 
 
418±34 
 
441±30 
 
<0.0001b,c,d,e 
 
16 weeks 
 
1089±60 
 
1045±58 
 
544±29 
 
721±19 
 
<0.0001b,c,d,e,f 
 
 
 
 
Supplementary Materials and Methods 
 
Human platelet lysate  
Platelet lysate supplement (PL) was produced by repeatedly freezing and thawing date-expired 
Human Platelet (SNBTS) packs to -80°C for 12 hours and thawing at room temperature.  The 
freeze/thaw cycles were repeated 3 times. Upon final thaw 10 platelet donation packs were pooled 
and centrifuged at 350g, before decanting the supernatants as 50mL aliquots and storing at -40°C.  
CFU-F assay 
Cells were diluted to 1000 cells/mL in HBSS. 100µL of cell suspension was plated in triplicate 
into 6 well plates (10 cm2, Corning, Cellbind) and CFU-F growth medium added [DMEM (Gibco), 
10% FCS (PAA), 1xNEAA (Gibco)]. Final cell density was thus 10 cells/cm2.  Plates were 
incubated at 37°C in 5% CO2 and assessed for outgrowth of cells by visual inspection every 2-3 
days. After 16-21 days, the wells were washed with PBS three times and the cells incubated with 
1% crystal violet solution (Sigma) for 15 mins. The wells were washed in excess PBS, allowed to 
air-dry, and colonies >2 mm in size were counted. 
Lineage differentiation  
MSCs were assessed for their differentiation capacity using the Human Mesenchymal Stem Cell 
Functional Identification Kit (R&D systems Cat# SC006). Briefly, MSCs were cultured for 7-21 
days in adipogenic, osteogenic (HUCPVC only), or chondrogenic differentiation media as detailed 
in the kit. The mature phenotype of adipocytes, osteocytes and chondrocytes were defined by 
staining as detailed in (61) (HUCPVC) or the binding of antibodies against FABP-4 and aggrecan 
supplied in the kit (adipocytes and chondrocytes respectively, Lipo-MSC) and were assessed by 
microscopy.   
RT2 Profiler PCR Arrays 
RT2 Profiler PCR Arrays Human Chemokines & receptors (Qiagen) were prepared and performed 
using a 7900HT (ABI) sequence detection system in accordance with manufacturer’s guidelines. 
Briefly, 102 μl of cDNA synthesis reaction was added to 650 μl of RT2 SYBR Green Mastermix 
and 548 µl of RNase-free water. Volumes were scaled up appropriately depending on sample size. 
10 μl of the PCR mastermix was added to each well of the RT2 PCR array. Once loaded, the plate 
was sealed using optical adhesive film. The plate was centrifuged at 1000g at RT to remove 
bubbles and run on an applied Biosystems 7900HT cycler.  Cycling conditions were as follows: 1 
cycle for 10 mins at 90⁰C followed by 40 cycles of 15s at 95⁰C/ 1 min at 60⁰C. Upon completion 
of the cycles a manual cycle threshold value of above background and within the linear phase was 
chosen. Data analysis was performed using QIAGEN’s GeneGlobe data analysis center. Any gene 
with a CT value of >35 was determined as undetectable. Data is presented as 2(-ΔCT) and normalized 
to the reference gene Beta-2 Microglobulin (B2M).  
Gene expression 
MSCs from the different tissues were plated at a density of 1x105/cm2 and grown for 24 hours in 
DMEM PL. Medium was removed and replaced with either complete medium or complete 
medium supplemented with 10 ng/mL IFN-gamma, IL-1b, TNF-a (R&D systems). Cells were 
incubated for a further 24 hours, and cells were harvested as above. Supernatants were frozen at -
80C for Luminex analysis (see below). 
Expression of chemokine, cytokine, chemokine receptor and cytokine receptor genes were 
assessed using quantitative PCR. Briefly, total RNA was isolated from cells using the RNeasy mini 
Kit protocol (QIAGEN) according to the manufacturer’s instructions - cells were lysed using RLT 
buffer, then homogenized using a QIAshredder spin column. Genomic DNA was digested as 
described in the protocol and RNA was eluted from the RNeasy spin column by adding 30-50μl 
of nuclease free water (QIAGEN). This was then quantified by using a nanodrop (Nanodrop 1000 
Thermo Scientific) and stored at -80⁰C. cDNA was synthesized using the high capacity RNA to 
cDNA kit (Life Technologies) to a final concentration of 168ng/µl and frozen at in -20 ⁰C until 
required for gene expression studies.  
Prior to use, cDNA was diluted 1 in 5 and then added to a mastermix consisting of PerfeCTa SYBR 
Green FastMix with ROX reference dye (VWR-International), primers and nuclease free water. 
Master mix (9µl) was dispensed into each well of the 384 well plate. Using a repeat dispenser 
pipette, 1μl of sample cDNA or –RT cDNA was dispensed into each well with the exception of 
no-template control wells, where cDNA was substituted with nuclease free water. Samples were 
run on an Applied Biosystem 7900HT thermal cycler. Cycling conditions were as follows: 95⁰C 
for 10 minutes (1x cycle) followed by 95⁰C for 3 seconds then 60⁰C for 30 seconds (x40 cycles). All 
primers were designed using Primer3 Input software version 4.0.0 (http://primer3.ut.ee/). Primer 
details in supplementary methods table 1.  
A reference gene Ribosomal Lateral Stalk Subunit P0 (RPLP0) which was most stably expressed 
throughout all samples was chosen for normalization. Any gene with a CT value of >35 was 
determined as undetectable. Data was expressed as expressed as 2(-ΔCT) against expression of 
RPLP0. 
Protein expression 
Conditioned media (24h) from the identical samples used for transcript analysis were collected 
and analyzed using a Luminex 100 analyzer (Bio rad) and premixed magnetic multi-analyte kits 
(R&D systems cat No. LXS-AHM-2) in accordance to the manufacturer’s instructions. Samples 
were diluted 2-fold with calibrator diluent. The pre-coated microparticle cocktail was added to 
each well of the 96 well microplates, followed by either 50μl sample or standard, sealed and placed 
on an orbital shaker for 2 hours at RT. The plates were washed twice with 100 μl/well wash buffer 
and then incubated with 50μl/well anti-biotin detector antibody for 1 hour at RT on the shaker then 
washed as before and 50μl/well of streptavidin-phycoerythrin was added and incubated for 30 
mins at RT. Microparticles were resuspended in 100μl/well of wash buffer and immediately read 
on the Bio-Rad analyser. Each microparticle bead region was designated and doublets excluded as 
stated on the certificate of analysis.  
  
Supplementary Methods Table 1 
Primer pairs 
Gene Name Left Primer Right Primer 
IDO gcaagaacgggacactttgc tgcctttccagccagacaaa 
CD274 gcctccactcaatgcctcaa ctgtcccgttccaacactga 
TGF-beta aagtggacatcaacgggttca gggtggccatgagaagca 
TSG-6 agcacggtctggcaaataca gcagcacagacatgaaatccaat 
HGF ttgcctgaaagatatcccgacaa cgggtgtgagggtcaagag 
CFH ggaagggagaatgggttgct gatgtccacagggccttttct 
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